$LGVN News

Longeveron Names Marie Washburn as Chief Financial Officer Effective On July 13; Lisa Locklear To Step Down As CFO

Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript

Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines Agency

Longeveron CFO Lisa Locklear Plans To Step Down, Effective July 10

Longeveron to Present at BIO International Convention 2026

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

Longeveron Inc. Q1 2026 Earnings Call Summary

LGVN Set for Success in 2026

Longeveron (LGVN) Q1 2026 Earnings Transcript

Longeveron Q1 2026 Earnings Call: Complete Transcript

Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Longeveron Q1 2026 Earnings Call: Complete Transcript

Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate

Maxim Group Downgrades Longeveron to Hold

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Phase 2b HLHS Cell Therapy Trial Clears Final Safety Review; Top-Line Results Expected August 2026

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)